SF3B1 and neoplasm: However, most drugs directed to modulate the splicing process have been designed to target SF3B1, which suggests the necessity of exploring additional targets among spliceosome components and splicing factors that exhibit consistent dysregulation in tumour pathologies and that could represent novel approaches to improve the management of this pathology.